A U.S. District Court in New York has approved the terms of a settlement between Del Global Technologies and its shareholders, dismissing all claims against Del and other defendants without any findings of liability or wrongdoing
A U.S. District Court in New York has approved the terms of a settlement between Del Global Technologies and its shareholders, dismissing all claims against Del and other defendants without any findings of liability or wrongdoing by any party, according to the company. Under the court-approved agreement, members of the class action will receive $2 million in cash and $2 million of subordinated promissory notes due in five years bearing interest at 6% per annum. Class action litigants will also receive 2.5 million shares of Del common stock with warrants to purchase one million shares of Del's common stock exercisable at $2 per share, expiring six years from the date of execution. Del Global develops and markets stationary and portable x-ray systems, as well as radio-frequency, mammography, and dental imaging systems. The company also makes high-voltage power conversion subsystems for medical and industrial applications.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.